TN2012000057A1 - Antibodies against the ectodomain of erbb3 and uses thereof - Google Patents

Antibodies against the ectodomain of erbb3 and uses thereof

Info

Publication number
TN2012000057A1
TN2012000057A1 TNP2012000057A TN2012000057A TN2012000057A1 TN 2012000057 A1 TN2012000057 A1 TN 2012000057A1 TN P2012000057 A TNP2012000057 A TN P2012000057A TN 2012000057 A TN2012000057 A TN 2012000057A TN 2012000057 A1 TN2012000057 A1 TN 2012000057A1
Authority
TN
Tunisia
Prior art keywords
erbb3
antibodies
receptor
antigen binding
binding fragments
Prior art date
Application number
TNP2012000057A
Other languages
English (en)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of TN2012000057A1 publication Critical patent/TN2012000057A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2012000057A 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof TN2012000057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (1)

Publication Number Publication Date
TN2012000057A1 true TN2012000057A1 (en) 2013-09-19

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000057A TN2012000057A1 (en) 2009-08-21 2012-02-09 Antibodies against the ectodomain of erbb3 and uses thereof

Country Status (21)

Country Link
EP (1) EP2467164A2 (es)
JP (1) JP5752687B2 (es)
KR (1) KR20120059568A (es)
CN (1) CN103002912A (es)
AU (1) AU2010284018C1 (es)
BR (1) BR112012003809A2 (es)
CA (1) CA2771744A1 (es)
CR (1) CR20120108A (es)
DO (1) DOP2012000044A (es)
EA (1) EA201200195A1 (es)
EC (1) ECSP12011740A (es)
IL (1) IL218097A0 (es)
IN (1) IN2012DN01518A (es)
MA (1) MA33582B1 (es)
MX (1) MX336091B (es)
NI (1) NI201200027A (es)
PE (1) PE20121585A1 (es)
SG (1) SG178509A1 (es)
TN (1) TN2012000057A1 (es)
WO (1) WO2011022727A2 (es)
ZA (1) ZA201201195B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
DK3351558T3 (da) * 2009-11-13 2020-06-02 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
EP2516469B1 (en) 2009-12-22 2016-03-30 Roche Glycart AG ANTI-HER3 Antibodies and uses thereof
CN102858335B (zh) 2010-03-11 2015-04-15 梅里麦克制药股份有限公司 Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
KR102027011B1 (ko) 2010-08-20 2019-09-30 노파르티스 아게 표피 성장 인자 수용체 3 (ｈｅｒ3)에 대한 항체
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
JP6033783B2 (ja) * 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
IN2014CN03042A (es) 2011-09-30 2015-07-03 Regeneron Pharma
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2788377B1 (en) * 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
WO2013124297A1 (en) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
NZ724013A (en) * 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan HER3 LIAISON AGENTS AND RELATED USES
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
AU2010284018C1 (en) 2015-10-15
CR20120108A (es) 2012-06-05
KR20120059568A (ko) 2012-06-08
ECSP12011740A (es) 2013-02-28
CA2771744A1 (en) 2011-02-24
AU2010284018A1 (en) 2012-03-22
ZA201201195B (en) 2015-07-29
JP2013506622A (ja) 2013-02-28
MX336091B (es) 2016-01-08
PE20121585A1 (es) 2012-11-29
SG178509A1 (en) 2012-04-27
IN2012DN01518A (es) 2015-06-05
AU2010284018B2 (en) 2014-06-05
CN103002912A (zh) 2013-03-27
EA201200195A1 (ru) 2012-12-28
DOP2012000044A (es) 2012-06-30
WO2011022727A3 (en) 2013-06-27
IL218097A0 (en) 2012-04-30
EP2467164A2 (en) 2012-06-27
WO2011022727A2 (en) 2011-02-24
MX2012002172A (es) 2012-05-29
MA33582B1 (fr) 2012-09-01
BR112012003809A2 (pt) 2019-09-24
NI201200027A (es) 2013-01-29
JP5752687B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (es) Anticuerpos contra erbb3 y usos de los mismos.
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
MX350957B (es) Moleculas de union especificas para her3 y usos de las mismas.
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
MX348637B (es) Anticuerpos y composiciones anti-her3.
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
EP3461847A8 (en) Humanized antibodies to liv-1 and use of same to treat cancer
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
CY1119154T1 (el) Anti-vla-4 αντισωματα
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
IN2014DN09717A (es)
IN2014CN04374A (es)
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
WO2018062402A8 (en) CMET MONOCLONAL BINDING AGENTS, THEIR MEDICINAL CONJUGATES AND USES THEREOF
NZ626296A (en) Compositions and methods for antibodies targeting factor p